Short answer
ADMA BIOLOGICS, INC. (ADMA) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Filing contains no earnings figures or operational metrics for fiscal year 2026.
ADMA BIOLOGICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing contains no earnings figures or operational metrics for fiscal year 2026
- Report signed August 5, 2026 by Adam S. Grossman, President and Chief Executive Officer
Item EX-99.1 · Exhibit EX-99.1
- 2Q revenue $124.4M, up 2%; ASCENIV $102.9M, up 24%, offsetting BIVIGAM revenue decline to $19.4M
- Gross margin expanded to 69% from 55%, driven by ASCENIV mix and yield-enhanced manufacturing
- GAAP net income $37.8M, up 11%; Adjusted EBITDA $61.8M, up 22%, indicating strong operating leverage
- FY2026 guidance reiterated: revenue $530M-$560M, Adjusted EBITDA $265M-$300M, despite competitive pricing pressure
- Share repurchases reached 13.8M shares year-to-date, or 5.3% of outstanding shares, supporting per-share value while SG-001 advances toward year-end pre-IND submission
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADMA BIOLOGICS, INC. 8-K filings
Get the next ADMA 8-K as it lands
Follow ADMA for push alerts, or ask the research agent what this filing means.